Baolingbao Biology (002286.SZ) has obtained the production license for lactulose active pharmaceutical ingredients.
BoLinbao (002286.SZ) issued an announcement. Recently, the company has obtained the "..." issued by the Shandong Provincial Drug Administration.
Baolingbao Biology (002286.SZ) announced that the company recently obtained the "Drug Production License" issued by the Shandong Provincial Drug Administration. The production address and scope are: No. 1 Dongwaihuan Road, High-tech Industrial Development Zone, Yucheng, Dezhou, Shandong; API (lactulose concentrated solution) (limited to registered use).
Obtaining the "Drug Production License" has accelerated the company's first API lactulose's follow-up declaration, registration, and listing process, marking the beginning of the company's diversified layout of APIs.
Related Articles

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


